In a significant move to enhance access to life-saving cancer medications, Ontario has accelerated public funding for five cancer treatments through its recently introduced Faster Access to Specialized Treatments (FAST) programme. This initiative addresses long-standing concerns from patients and pharmaceutical companies regarding the delays in making new therapies available following regulatory approval.
Expansion of Coverage for Critical Cancer Drugs
The Ontario government is set to unveil the names of five cancer drugs that have qualified for the FAST programme, which aims to expedite the process of bringing oncology innovations to patients. Among the medications included are treatments for various forms of lung cancer, prostate cancer, leukemia, and lymphoma. Notably, one of the newly funded therapies is a promising option for both colorectal and liver cancer, expanding the scope of available treatments to cover six distinct cancer types.
Lisa Machado, who heads the Canadian CML Network—a non-profit organisation supporting patients with chronic myeloid leukaemia—has expressed strong support for the initiative. She highlighted the programme’s quick approval of Scemblix, a targeted therapy for newly diagnosed patients, stating, “Whether it’s CML or another cancer, more options mean better lives and better outcomes for patients.” This sentiment echoes the urgent need for timely access to effective treatments.
Addressing Delays in Medication Access
Historically, Canadian patients have faced lengthy wait times—averaging 2.5 years—from Health Canada approval to public funding of new drugs. This delay is among the longest in the G7 nations. Critics argue that while Canada’s stringent approval process helps in securing reasonable drug prices and prioritising high-evidence therapies, it often prolongs critical access for patients in need.
The FAST programme seeks to alleviate this issue by removing a step in the funding process. It allows Ontario to reimburse certain cancer therapies identified through Project Orbis, an international regulatory collaboration, even before the pan-Canadian Pharmaceutical Alliance (pCPA) finalises confidential pricing agreements with drug manufacturers. This shift aims to significantly reduce the time it takes for patients to receive necessary treatments.
Quick Turnaround on Drug Pricing
In a notable case, Scemblix was approved by Health Canada as a first-line therapy in late July. Ontario commenced funding for this treatment on November 7, well ahead of the pCPA’s pricing talks with Novartis AG, the drug’s manufacturer, which began in mid-December. The other therapies included in the pilot project are Tagrisso for lung cancer, Nubeqa for prostate cancer, Calquence for lymphoma, and a combination of Opdivo and Yervoy for colorectal and liver cancer. While these drugs were previously available under more limited conditions, the FAST initiative has broadened their accessibility.
Mauro Chies, CEO of the pCPA, noted that the swift negotiation of pricing agreements for these drugs—often completed in less than seven weeks—demonstrates the efficacy of the new approach. “Agreements for these drugs can be leveraged by all our federal, provincial, and territorial members, meaning all drug plans can take advantage of the same lower price,” he stated.
The Ongoing Challenge of Drug Pricing
Despite the progress, the high prices of new cancer treatments continue to pose challenges for Canadian public drug plans. Scemblix, for instance, carries a list price of $4,760 per 28-day cycle, although negotiated discounts can lower this cost. Dennis Kim, a senior hematologist at Toronto’s Princess Margaret Cancer Centre, advocates for the rapid funding of Scemblix, citing its reduced side effects compared to alternative therapies. He added that having more treatment options empowers both doctors and patients in their fight against cancer.
Why it Matters
This pilot project represents a critical step in reforming how Canada approaches the funding of new cancer therapies. By streamlining access to innovative treatments, Ontario is not only addressing the urgent needs of patients but also setting a precedent that could influence drug approval processes across the country. The FAST programme’s focus on expediting access while maintaining rigorous standards for pricing and effectiveness could redefine the landscape for cancer care in Canada, ultimately saving lives and improving outcomes for countless individuals battling this formidable disease.